NO995382L - Lentivirus baserte genoverfoeringsvektorer - Google Patents

Lentivirus baserte genoverfoeringsvektorer

Info

Publication number
NO995382L
NO995382L NO995382A NO995382A NO995382L NO 995382 L NO995382 L NO 995382L NO 995382 A NO995382 A NO 995382A NO 995382 A NO995382 A NO 995382A NO 995382 L NO995382 L NO 995382L
Authority
NO
Norway
Prior art keywords
vector
eiav
expression system
genome
defective
Prior art date
Application number
NO995382A
Other languages
English (en)
Other versions
NO995382D0 (no
Inventor
John C Olsen
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of NO995382D0 publication Critical patent/NO995382D0/no
Publication of NO995382L publication Critical patent/NO995382L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO995382A 1997-05-13 1999-11-03 Lentivirus baserte genoverfoeringsvektorer NO995382L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4689197P 1997-05-13 1997-05-13
PCT/US1998/010144 WO1998051810A1 (en) 1997-05-13 1998-05-12 Lentivirus-based gene transfer vectors

Publications (2)

Publication Number Publication Date
NO995382D0 NO995382D0 (no) 1999-11-03
NO995382L true NO995382L (no) 2000-01-13

Family

ID=21945954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995382A NO995382L (no) 1997-05-13 1999-11-03 Lentivirus baserte genoverfoeringsvektorer

Country Status (13)

Country Link
US (3) US6277633B1 (no)
EP (1) EP0981636B1 (no)
JP (1) JP4390860B2 (no)
KR (1) KR100556864B1 (no)
CN (1) CN1247788C (no)
AT (1) ATE291632T1 (no)
AU (1) AU741747B2 (no)
CA (1) CA2288328A1 (no)
DE (1) DE69829471T2 (no)
IL (1) IL132463A0 (no)
NO (1) NO995382L (no)
NZ (1) NZ500740A (no)
WO (1) WO1998051810A1 (no)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076613A1 (en) * 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
ES2245042T3 (es) * 1997-09-24 2005-12-16 The Regents Of The University Of California Vectores de lentivirus de no primates y sistemas de empaquetamiento.
AU760287B2 (en) * 1997-12-22 2003-05-08 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (EIAV) based
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO2000040741A2 (en) * 1999-01-07 2000-07-13 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health Lentivirus vector system
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
AU4012100A (en) * 1999-03-16 2000-10-04 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
CN1173036C (zh) * 1999-04-21 2004-10-27 卫生部艾滋病预防与控制中心 马传染性贫血病毒驴白细胞弱毒疫苗株的全长基因序列
US8017590B1 (en) 1999-10-22 2011-09-13 Sanofi Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1282702B1 (en) * 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
BR0113745A (pt) * 2000-09-09 2004-03-02 Akzo Nobel Nv Vacina, teste diagnóstico e métodos para imunizar mamìferos e para preparar uma vacina
GB0024550D0 (no) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
AU2001297735A1 (en) * 2000-11-16 2002-10-15 Rigel Pharmaceuticals, Inc. In vitro transcribed retroviral genomes, methods for their production and methods of use
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
JP4413495B2 (ja) 2001-03-13 2010-02-10 ノバルティス アクチエンゲゼルシャフト レンチウィルスパッケージング構築物
US7211247B2 (en) * 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
IL160132A0 (en) 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
IL161229A0 (en) 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
AU2002357791B9 (en) 2001-12-05 2008-09-25 The J. David Gladstone Institutes Robotic microscopy systems
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1499736B1 (en) * 2002-04-26 2009-03-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improved chimeric glycoproteins and pseudotyped lentiviral vectors
WO2004044157A2 (en) * 2002-11-12 2004-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Human Services, The National Institutes Of Health Gp64-pseudotyped vectors and uses thereof
CA2506798C (en) * 2002-11-22 2013-01-22 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US8026819B2 (en) * 2005-10-02 2011-09-27 Visible Assets, Inc. Radio tag and system
US20060259997A1 (en) * 2003-08-29 2006-11-16 Shinji Iijima Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
US8105575B2 (en) * 2006-10-10 2012-01-31 Viromed Co., Ltd. Expression vectors with improved safety
EP2089513A1 (en) 2006-12-07 2009-08-19 Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
CN101705246B (zh) * 2007-04-29 2012-06-27 中国农业科学院哈尔滨兽医研究所 慢病毒基因转移载体、其制备方法和应用
JP5543921B2 (ja) 2007-10-15 2014-07-09 コリドン ピーティーワイ リミテッド 免疫応答をモジュレートするための発現系
JP2011503207A (ja) 2007-11-16 2011-01-27 サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
CA2751332C (en) 2009-02-03 2024-04-02 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
CN101532031B (zh) * 2009-03-03 2011-04-20 上海吉盛制药技术有限公司 非整合慢病毒载体系统及其制备与应用
JP2013505232A (ja) 2009-09-16 2013-02-14 スティヒティング ヘット ネーデルラント カンカー インスティテュート 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2319918B1 (en) * 2009-11-10 2013-01-16 Centre National De La Recherche Scientifique Lentiviral-based vector and its use in directed evolution of genomic regions, genes and polynucleotides
WO2011066578A1 (en) * 2009-11-30 2011-06-03 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
CA2876293C (en) 2012-06-27 2023-10-10 Arthrogen B.V. Combination for treating an inflammatory disorder
ES2698522T3 (es) 2012-07-12 2019-02-05 Proqr Therapeutics Ii Bv Oligonucleótidos para la realización de un cambio en la secuencia de una molécula de ARN diana presente en una célula viva
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
US9730996B2 (en) 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
WO2014152321A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
WO2015069469A1 (en) 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CA2974235A1 (en) 2015-01-07 2016-07-14 Universitat Autonoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
CN108883105B (zh) 2015-10-23 2022-07-15 杰克逊实验室 烟酰胺用于治疗和预防眼部神经退行性疾病如青光眼
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
JP7110108B2 (ja) 2015-12-09 2022-08-01 ジンガン メディスン（オーストラリア） プロプライアタリー リミティド 治療用免疫調節組成物
WO2017212074A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
JP2020506695A (ja) 2017-01-30 2020-03-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 糖原病を処置するための組換えウイルスベクター
EP3630160A1 (en) 2017-05-24 2020-04-08 Universitat Autònoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
EP3648776A4 (en) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CHS-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR THE THERAPY OF DISORDERS
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3886759A1 (en) 2018-11-26 2021-10-06 Massachusetts Institute of Technology Compositions and methods for immune tolerance
US20210386870A1 (en) 2018-11-26 2021-12-16 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy
KR20220016100A (ko) 2019-05-31 2022-02-08 유니버시타트 아우토노마 데 바르셀로나 인슐린 유전자 요법
BR112022021918A2 (pt) 2020-04-27 2023-03-14 Univ Iowa Res Found Composições e métodos para o tratamento de fibrose cística
KR20230017845A (ko) 2020-05-26 2023-02-06 유니버시타트 아우토노마 데 바르셀로나 중추 신경계 장애에 대한 섬유아세포 성장 인자 21(fgf21) 유전자 요법
WO2021242719A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
US20240018487A1 (en) 2020-12-10 2024-01-18 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells
CA3206590A1 (en) 2021-01-30 2022-08-04 Maria Fatima Bosch Tubert Gene therapy for monogenic diabetes
WO2022221462A1 (en) 2021-04-13 2022-10-20 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
EP4089171A1 (en) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Recombinant tert-encoding viral genomes and vectors
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
CA3226001A1 (en) 2021-07-16 2023-01-19 Anton Jan Van Zonneveld Oligonucleotide for inhibiting quaking activity
WO2023212683A1 (en) 2022-04-29 2023-11-02 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024052413A1 (en) 2022-09-07 2024-03-14 Universitat Autònoma De Barcelona Beta-hexosaminidase vectors
WO2024100136A1 (en) 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024149284A1 (en) * 2023-01-10 2024-07-18 Nanjing Legend Biotech Co., Ltd. Regulatory sequences and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5376542A (en) 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
CA2158936C (en) 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5750396A (en) 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
US6150511A (en) 1995-05-09 2000-11-21 Fox Chase Cancer Center Chimeric enzyme for promoting targeted integration of foreign DNA into a host genome
EP0835320A1 (en) 1995-05-10 1998-04-15 Introgene B.V. Improved retroviral vectors, especially suitable for gene therapy
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CZ137399A3 (cs) 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors

Also Published As

Publication number Publication date
US20010044149A1 (en) 2001-11-22
JP4390860B2 (ja) 2009-12-24
JP2002510199A (ja) 2002-04-02
KR20010012543A (ko) 2001-02-15
US20030148522A1 (en) 2003-08-07
US6521457B2 (en) 2003-02-18
CA2288328A1 (en) 1998-11-19
EP0981636B1 (en) 2005-03-23
AU741747B2 (en) 2001-12-06
US6277633B1 (en) 2001-08-21
ATE291632T1 (de) 2005-04-15
KR100556864B1 (ko) 2006-03-10
IL132463A0 (en) 2001-03-19
NZ500740A (en) 2001-02-23
CN1261404A (zh) 2000-07-26
NO995382D0 (no) 1999-11-03
EP0981636A1 (en) 2000-03-01
AU7577798A (en) 1998-12-08
WO1998051810A1 (en) 1998-11-19
DE69829471T2 (de) 2006-04-13
CN1247788C (zh) 2006-03-29
DE69829471D1 (de) 2005-04-28

Similar Documents

Publication Publication Date Title
NO995382L (no) Lentivirus baserte genoverfoeringsvektorer
Zaiss et al. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy
EP0512017B1 (en) Vaccines
Cui et al. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function
GB2331522B (en) Lentiviral vectors
Heinkelein et al. Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors
EP0702716A4 (en) GENTHERAPY FOR HIV INFECTION AND AIDS WITH THE AID OF RIBOZYMS
ATE211766T1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
WO2001081608A3 (en) Viral vectors for use in monitoring hiv drug resistance
WO2003092594A3 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
JP2003508017A5 (no)
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
US12091674B2 (en) Lentiviral vector and method for delivering exogenous RNA by the lentiviral vector
Pietschmann et al. An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
FR2606029B2 (fr) Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
AU4952500A (en) Packaging cell
WO2000040741A3 (en) Lentivirus vector system
JP2004524805A5 (no)
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination
Bansal et al. Characterization of the R572T point mutant of a putative cleavage site in human foamy virus Env
Joshi et al. Efficient replication, integration, and packaging of retroviral vectors with modified long terminal repeats containing the packaging signal
AU8188187A (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application